

by Bernard Dixon

## LESSONS FOR MEDDLERS

Next month marks one decade since that historic Gordon Research Conference following which Maxine Singer and Dieter Sol, the two cochairmen, wrote to the president of the National Academy of Sciences regarding the newly developed "ability to join together, covalently, DNA molecules from diverse sources." Outlining possible benefits from this technique, they also expressed disquiet about theoretical hazards to laboratory workers and the public from novel organisms spawned as a result of such a biologically unprecedented procedure. Publicized through the columns of *Science* (181: 1114), that letter triggered off the furor which led to the Asilomar conference in February 1975. There followed an acrimonious public debate concerning scary monsters, and an acrimonious professional debate over prudent regulations for recombinant DNA manipulations.

Ten years later, with guidelines relaxed and those hypothetical dangers having been dismissed as unreal or unimportant, there is a tendency to see the entire controversy as a storm in a teacup. Some scientists who played a major role in ventilating honest apprehensions now feel they went too far, attracting grotesquely ill-informed political opposition and diverting their energies away from the laboratory bench and towards committee rooms and public platforms. Given the opportunity, next time around they would probably decide not to blow the whistle.

If such (understandable) weariness were to make today's biotechnologists underrate political and public concerns, the results could be calamitous. Logic is far from being the only motive force behind scientific and commercial development. British Petroleum discovered that truth some years ago when a combination of post-Seveso environmental sensitivity and pressure from the soybean lobby persuaded the Italian government to ban BP from operating its single-cell protein plant in Sardinia. The company eventually pulled out of microbial food altogether. Total cost: £100 million.

But what of rationality and irrationality about gene splicing today? On the side of sanity, we have a long catalogue of reassurance: the mediocrity of *Escherichia coli* K-12 as an Andromeda strain, the development of totally safe hosts for recombinant DNA work, the presence of introns in eukaryotic genes which thus cannot be expressed in prokaryotes, the dismal failure of simulated disasters such as animal infection with *E. coli* containing polyoma genes, and Stanley Cohen's work showing that DNA maneuvers of the sort which caused Erwin Chargaff and fellow critics such anxiety are not as radically new as was thought.

**Bernard Dixon, Ph.D., is a microbiologist and regular columnist for BIO/TECHNOLOGY. He is a former editor of New Scientist.**

There is another, broader argument. Any critical extra-terrestrial monitoring our affairs would surely be astonished by the contrast between intense, recent concern over manipulations conducted under conditions of cast-iron containment, and the manifold ways in which we have modified terrestrial genomes during centuries past. In their recent, thought-provoking book *Genetic Consequences of Man Made Change* (Academic Press), J. A. Bishop and L. M. Cook show just how drastic such changes, conscious and otherwise, have been. Consider, for example, the monoculture of astronomical areas of genetically identical plants which characterizes modern agriculture. Think of the proliferation of heavy metal-resistant species caused by the dumping of mining wastes on the earth's surface, and other toxic materials in the environment.


Above all, there is the appalling spread of bacterial drug resistance produced by uncontrolled, indiscriminate use of antibiotics. As Stuart Levy observed recently in *The Lancet* (1982, 2: 83), this now poses a serious threat to public health throughout the world. Looking back, it is difficult to disagree with the sentiments of the bacteriologist E. S. Anderson—expressed early on in the past decade's debate—that such feckless disregard for the ill-consequences of antibiotic misuse was infinitely more dangerous than any risks arising from recombinant DNA work done in high security facilities.

Evidence for the safety of a new technology, plus favorable comparisons with thoughtless follies elsewhere, does not, however, constitute a case for boundless buoyancy. On the one hand, as Ditta Bertels and colleagues pointed out recently (*Trends in Biochemical Sciences*, 1983, 8: 78), some of the reassuring evidence that led to the relaxation of guidelines is itself being reassessed. Thus, they argue, the discovery of processed genes without introns in higher animals resurrects one of those earlier anxieties. "During the intervening period of four years most of the stringency conditions which were initially incorporated in various local and national guidelines have been scrapped," they write. "Until more is known about the expression of cloned processed genes in bacteria, uncertainty about the biohazard of cloning animal DNA will remain."

So much for the intellectual case. Equally significant for those scientists and administrators involved in biotechnology is the need for caution in a wider sense. Just one accident during "scale-up," for example, could forfeit public confidence and set back R&D spectacularly. Similarly, just one mischievous television program might easily renew and reinforce the very worst fears about what Chargaff once called "genetic meddling."

In considering such possibilities, we would be wise to bear in mind the capricious, as well as substantive, factors which held to propel ideas into the

Continued on page 299



**Bernard Dixon, Ph.D.**

**COMMENTARY** (continued from page 300)

public arena and make them fashionable concerns. Who, for example, would have foreseen that, after being overshadowed by nuclear power for a decade or more, nuclear weaponry would suddenly again become a major political issue in the Western world? Who would have prophesied the emergence of animal experimentation as a passionate talking-point in Europe? How to account for the furor surrounding the world's first round of heart transplants in the late 1960s, compared with the conspicuous lack of public interest about the more recent second round?

As BP found at great cost in Sardinia, it is at least as important to grapple with social and political ramifications as it is to get the science and technology right. Perhaps (in addition to the ecologist I suggested recently) every company investing in biotechnology should have a first-rate sociologist on board. Or even a clairvoyant. ■

**SALES REPRESENTATIVES**

**U.S. Office**

Henry Dale  
Group Advertising Director  
15 East 26 Street  
New York, NY 10010  
(212) 689-9140

**West Coast**

Gretchen Hasse  
57 Post Street  
Suite 712-715  
San Francisco, CA 94104  
(415) 392-6794

**U.K. Office**

Andy Sutherland  
4 Little Essex Street  
London WC2R 3LF  
(1) 836-6633

**Dave Heidersbach**

119 West Bellevue Drive  
Pasadena, CA 91105  
(213) 796-9200

**New England**

Charles Lynch  
61 Adams Street  
Braintree, MA 02184  
(617) 848-9306

**Canada**

Peter Drake  
32 Front Street West  
Suite 201  
Toronto, Ontario M5J 1C5  
(416) 364-1623

**Upstate New York**

Donald E. Northrup  
RD #3 Box 6  
Dalton, PA 18414  
(717) 563-2145

**Australia**

Gus Bartel  
PO Box 15  
The Patch, Victoria  
Australia 3792

**Mid-Atlantic**

Daniel Adams  
3608 Chapel Road  
Newton Square, PA 19073  
(215) 353-6191

**West Germany & Austria**

Franz Schrecklinger  
TMW Top Media  
Werbegesellschaft GmbH  
Frankfurt (611) 726046

**Mary Grunmeier**

Box 1068  
Edison, NJ 08818  
(210) 572-9018

**Holland & Belgium**

Mrs. Adele Struyck  
G. Arnold Teesing BV  
Amsterdam (020) 2636 15

**Southwest**

Bill Powell  
17202 Lazy Hill Lane  
Spring, TX 77379  
(713) 376-2368

**Switzerland**

Werner Stahli  
Agentur IFF AG  
Schaffhausen (053) 45821

**Southeast**

Brinker & Brinker  
5353 N. Federal Highway  
Fort Lauderdale, FL 33308  
(305) 771-0064

**Scandinavia**

Andrew Karnig  
Andrew Karnig &  
Associates AB  
Stockholm (08) 51 68 60

**Midwest**

Didier & Broderick  
255 Revere Drive  
Suite 105/106  
Northbrook, IL 60062  
(312) 498-4520

**Japan**

Mashy Yoshikawa  
Orient Echo, Inc.  
Tokyo 541-4923

**Biotechnology Patent Digest**

... **COMPREHENSIVE, FAST, AND COST-EFFECTIVE**

**BIOTECHNOLOGY PATENT DIGEST**, a bi-weekly periodical providing information on patents in **biotechnology and related fields** in an understandable format, is **faster** than on-line information sources, provides **full-text** information, and is the most **cost-effective** source of patent information found anywhere.

**Features include:**

- **RECENT PATENTS** — Patents issued during the previous two weeks are listed and essential information is presented in a concise format for easy scanning. Keywords alert you to patents of interest.
- **PATENT HIGHLIGHTS** — Patents describing major advances in general methodology, new processes, or new products are highlighted. Selected information may include claims, experimental (examples of the art), and drawings.
- **RELATED PATENTS** — Patents from related fields and technologies are presented permitting you to compare biological and conventional technologies.
- **PATENTS FROM THE PAST** — Important patents in biotechnology issued in past decades are described and even reproduced in original form. Section provides a historical perspective to new patents and documents past achievements. Best available copies are reproduced.
- **PATENT DECISIONS AND RULINGS** — Decisions by major patent organizations and rulings by courts are described in an abbreviated and understandable form. Section presents legal aspects to scientists and research administrators in relatively free non-technical language.
- **PATENTS AVAILABLE FOR LICENSING** — Patents available for licensing are listed.
- **INVENTOR'S WORD** — Personal accounts of major inventions and developments by inventors are given to stimulate discussion and improve the innovation process.
- **NEWS BRIEF** — General items of interest appear — new publications, forthcoming conferences, activities of scientific societies and trade associations, file intelligence, etc.

**Special Feature:**

- **PATENT ANALYSIS** — Brief but highly informative analyses of major techniques, processes, products, firms, and industrial sectors are presented.

**OSKAR R. ZABORSKY, EDITOR**  
**U.S. NATIONAL SCIENCE FOUNDATION**  
Washington, D.C., U.S.A.

**EDITORIAL BOARD**

**ROBERT W. COUGHLIN**  
University of Connecticut

**ARNOLD L. DEMAIN**  
Massachusetts Institute  
of Technology

**RALPH W. F. HARDY**  
E. I. du Pont de Nemours  
& Company

**ZSOLT HARSANYI**  
E. F. Hutton & Co., Inc.

**ALEXANDER HOLLAENDER**  
Council for Research Planning  
in Biological Sciences

**DALE H. HOSCHEIT**  
Schuyler, Banner, Birch,  
McKie & Beckett

**JOHN H. LITCHFIELD**  
Battelle Columbus  
Laboratories

**WILLIAM D. MAXON**  
The Upjohn Company

**JOHN H. RAUBITSCHKE**  
U.S. Department of Army

**MAX TISHLER**  
Wesleyan University

**GEORGE T. TSAO**  
Purdue University

**HAROLD C. WEGNER**  
Wegner and Bretschneider

If you're interested in biotechnology, then **BIOTECHNOLOGY PATENT DIGEST** is for you!

- **COMPREHENSIVE** — presents **full-text** information from patents — comprehensive coverage not obtainable from any other source except original patents. All relevant sectors of biotechnology — both traditional and emerging — are covered.
- **FAST** — presents information as soon as it is made publicly available. Easy scanning format lets you quickly review patents of interest.
- **COST-EFFECTIVE & SELECTIVE** — highlights significant patents in biotechnology and related fields. Yet your cost is only a few dollars (\$4.90) per week.

The Digest (ISSN 0730-1057) is available from the OMEC Publishing Company, P.O. Box 446, McLean, VA 22101. Subscription price is \$255 per year (26 issues) for U.S. and Canada; \$285 per year elsewhere (including air delivery). Sample copies available. Circle No. 6 on Reader Service Card